SYNGENE384.00

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹15,471 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+2.6+3.5
EBITDA-11.8-4.8
Net Income-36.2-21.2
Total Assets+3.8+7.1
Total Equity+2.4+6.6
Free Cash Flow+37.6+1.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.